|
ECOG 1411
Intergroup Randomized Phase II Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide +Rituximab Consolidation (RBV → LR)
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Eastern Cooperative Oncology Group (ECOG)
ECOG 1411 at clinicaltrials.gov
Immunomedics
A Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Immunomedics
DR12Imm-IM-T-hll1-DOX-02 at clinicaltrials.gov
MEK Inhibitor
A Single-Arm Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-cell Lymphoma
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: National Cancer Institute (NCI)
UM12NIH (MEK Inhibitor) at clinicaltrials.gov
Janssen MCL2001
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Janssen Research & Development, LLC
Janssen MCL2001 at clinicaltrials.gov
SWOG 1108
Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
INVESTIGATOR: Muthalagu Ramanathan, MD
SPONSOR: Southwest Oncology Group
SWOG 1108 at clinicaltrials.gov
Genentech GAO4915g
A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients with Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated with GA101 (RO5072759) in Combination with CHOP Chemotherapy
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Genentech
GAO4915g at clinicaltrials.gov
ECOG E2408
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Eastern Cooperative Oncology Group (ECOG)
ECOG E2408 at clinicaltrials.gov
Northwestern University
Protocol NU11H01: A phase II trial of sequential SGN35 therapy with Adriamycin, vinblastine, and dacarbazine (S-AVD) for older patients with untreated Hodgkin lymphoma
INVESTIGATOR: Andrew Evens, DO, MSc
SPONSOR: Northwestern University
Northwestern University at clinicaltrials.gov
|